Oral OSA Drug Candidate ‘Exceeded Expectations’ in Phase 2 Trial
The drug candidate demonstrated statistically significant reductions in AHI and improvements in oxygenation, coupled with positive patient-reported outcomes.
Read MoreThe drug candidate demonstrated statistically significant reductions in AHI and improvements in oxygenation, coupled with positive patient-reported outcomes.
Read More‘In addition to not being very safe, these drugs also make sleep quality worse in ways that may be detrimental to brain health.’
Read MoreAchaemenid Innovations’ wireless oral cavity sensor detects oxygen saturation, pulse rate, actigraphy, and oral appliance use, aiming to overcome skin-tone and environmental limitations of fingertip oximetry.
Read MoreMass General Brigham researchers identified seven molecules in the blood linked to excessive daytime sleepiness, including factors related to diet and hormones.
Read MoreInsights from a retrospective review of children who underwent hypoglossal nerve stimulator implant surgeries.
Read More